You are here: Industry Insights > cancer

News List

AZ’s Imfinzi scores FDA breakthrough therapy designation in wake of major trial failure pharmafile
August 01, 2017
Still reeling from the public reaction to the flop of its key Mystic trial, where its injectable immunotherapy drug Imfinzi (durvalumab) failed to show any clinically relevant efficacy in stopping lung cancer progression,
Imfinzi wins breakthrough therapy designation europeanpharmaceuticalreview
August 01, 2017
AstraZeneca and MedImmune, have today announced that the US Food and Drug Administration has granted breakthrough therapy designation for Imfinzi for the treatment of patients with locally-advanced, unresectable non-small cell lung cancer…
CRUK brings commercialisation arm in-house pharmatimes
July 31, 2017
Cancer Research UK has brought its commercialisation arm, Cancer Research Technology (CRT), together with its research funding teams to form a new in-house division called Research and Innovation.
Shooting for the moon: The National Cancer Institute’s Formulary pharmafile
July 31, 2017
Pharmafile spoke to National Cancer Institute's (NCI) Jason Christofaro and Sherry Ansher regarding the development of an agent formulary and its role as part of the wider Moonshot Initiative.
Sandoz to improve treatment access to children with cancer in four developing nations pharmaceutical-technology
July 31, 2017
Novartis Group division Sandoz has expanded its partnership with UK-based charity World Child Cancer to improve access to treatment, as well as optimise survival outcomes for children suffering from cancer in four developing nations.
AZ, Merck link to develop and commercialise cancer drugs pharmatimes
July 28, 2017
AstraZeneca and Merck & Co have announced a global strategic oncology collaboration to co-develop and co-commercialise the former’s Lynparza and selumetinib for multiple cancer types.
EU OKs first-line use of AZ’ Faslodex pharmatimes
July 28, 2017
EU regulators are permitting the use of AstraZeneca’s breast cancer drug Faslodex at an earlier stage of the treatment pathway in patients with certain forms of the disease.
AZ's 'blockbuster' lung cancer drug fails, Q2 revenue falls pharmafile
July 28, 2017
Imfinzi and immune checkpoint blocker tremelimumab were no better at stopping lung cancer progression than standard chemotherapy in patients expressing protein PD-L1 in over 25% of their cancer cells.
New research reveals genetic mutations in smoking-related cancers pharmafile
July 28, 2017
Researchers at the Wake Forest School of Medicine in the US have made a big discovery which could help explain the role of gene mutations in smoking-related cancers and why
Blow for AstraZeneca as cancer combination fails pharmaphorum
July 27, 2017
After several years of growing expectation, AstraZeneca’s long-awaited MYSTIC immune-oncology trial has failed to show benefit over standard lung cancer therapy.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 87 88 Next page